CHAPEL HILL, N.C., Sept. 3 /PRNewswire/ — The Medical Affairs
function arguably plays the most critical role in a
biopharmaceutical organization, with heavy responsibilities across
areas such as clinical development, scientific publications, KOL
development, and medical education. These areas must operate
effectively for new products to succeed. Appropriate spending
across these activities is one of the challenges facing the Medical
Affairs function as it attempts to balance its different roles
across the organization.
According to recent Best Practices, LLC research, 37 percent of
Medical Affairs spending, on average, is allocated for
medical/clinical research, with the top quartile of respondents
spending more than 60 percent for the clinical function. Meanwhile,
medical education takes up 18 percent of allocations, according to
the study.
“Medical Affairs Resources, Structures and Trends” highlights
trends in budget and staffing for Medical Affairs groups to help
leaders in Medical Affairs effectively and efficiently meet the
myriad roles of the function. The 45-page report also identifies
current organizational approaches for Medical Affairs and current
trends and challenge the function is facing.
Twenty-two organizations participated in this study, including:
Amgen, AstraZeneca, Bayer Healthcare, BMS,
Genentech, J&J Vision Care, Novartis, Novo Nordisk,
Schering-Plough, Solvay, Vertex and others.
“Medical Affairs
Resources, Structures & Trends” covers key topics such
as:
- Organizational Structure
- Reporting Relationship
- Job Level of Group Leader
- Geographic Span
- Budget Allocation by Medical Affairs Function
- Percent of Budget Allocated for Outsourcing
- Recent and Anticipated Changes in Resource Levels
- Impact of Medical Affairs Functions on Company Success
‘/>”/>
